Definition and Clinical Features Top
Vasospastic angina (Prinzmetal variant angina) is a type of angina in which chest pain is caused by transient ischemia secondary to spontaneous coronary artery spasm. Chest pain generally occurs at rest and usually in the absence of flow-limiting coronary stenoses.
Symptoms include chest pain occurring at rest, commonly in the late night or early morning hours, which is frequently transient and lasts between 5 and 15 minutes (pain characteristics: see Stable Angina Pectoris). On occasion, it may also develop on exertion, although this is less common. Other associated symptoms may include nausea, diaphoresis, palpitations, dyspnea, and lightheadedness.
Diagnosis is based on the occurrence of unprovoked chest pain at rest with accompanying ST-segment elevation (less commonly depression) on electrocardiography (ECG) and absence of significant coronary artery stenosis on coronary angiography. If an episode occurs during coronary angiography, coronary spasm may be directly observed during the procedure. Interventionalists can provoke coronary spasm via medications such as acetylcholine, ergonovine, or via hyperventilation, but this is not done commonly and only performed when the diagnosis is unclear.
In patients with recurrent pain, Holter monitoring may reveal ST-segment changes with pain. Whether ST-segment elevation or ST-segment depression is seen depends on the severity of spasms: full occlusion causes ST-segment elevation, while a less severe spasm may cause ST-segment depression. Rises in the levels of biomarkers of ischemia depend on the duration of the spasm. While most times the spasm is transient, a prolonged spasm may lead to actual infarction and arrhythmia in up to 25% of patients.
1. Modification of risk factors, particularly smoking cessation.
2. Low-dose acetylsalicylic acid (ASA).
3. High-dose oral calcium channel blockers: Diltiazem 120 to 360 mg/d, verapamil 240 to 480 mg/d (Table 3.11-14). If treatment with 1 calcium channel blocker is not effective, add another calcium channel blocker of a different group or a long-acting nitrate (Table 3.11-13).
4. Nonselective beta-blockers are contraindicated as they may exacerbate vasospasm.
Percutaneous intervention is not recommended as the first-line therapy for patients with coronary vasospasm and nonobstructive coronary disease. Consideration may be given to percutaneous coronary intervention (PCI) if a significant plaque (≥70%) is present and if the plaque is thought to be a trigger for localized vasospasm with the patient developing pain at rest. Further, PCI of a vasospastic segment may be of benefit in patients who are refractory to medical therapy if the vasospastic segment is clearly visualized on the diagnostic catheterization. Outcomes overall are variable as vasospasm may occur in a different section of the artery, and thus medical therapy is considered the first-line treatment. Vasospasm-associated severe arrhythmias may require treatment with a pacemaker or implantable cardioverter-defibrillator (ICD).
Among patients with vasospastic angina, 95% survive 5 years from diagnosis. Prognosis is worse in patients with concurrent atherosclerotic plaque and in those with vasospasm-induced ventricular fibrillation.